How pharma IP teams, portfolio managers, and R&D leads identify, evaluate, and time market entry opportunities across branded, 505(b)(2), and […]
Biopharmaceutical Market Entry: The Complete IP, ANDA, and 505(b)(2) Playbook Read Post »
EXECUTIVE SUMMARY When a patent expires on the first-in-class drug in a therapeutic area, two things happen simultaneously. The originator’s
The pharmaceutical business operates on a fundamental cycle of innovation, patent-protected exclusivity, and eventual commoditization. For executives in business development,
1. The Structural Economics of Pharmaceutical Outsourcing Why Vertical Integration Failed The pharmaceutical industry did not arrive at its current
1. Why Most Drug Launches Fail Before They Begin Roughly two-thirds of new drug launches miss their first-year sales forecasts,
The Definitive Pharmaceutical Drug Launch Playbook: Every Critical Mistake, Dissected Read Post »
The Drug Price Competition and Patent Term Restoration Act of 1984 was not, in any conventional sense, a health policy
Every year, the U.S. pharmaceutical market transfers hundreds of billions of dollars in revenue from branded monopolies to generic competitors.
Executive Summary: A Structural Recalibration of Global Power The global pharmaceutical sector is currently witnessing a definitive structural recalibration. The
The Influence of Emerging Markets on the Pharmaceutical Industry Read Post »
I. Executive Summary Drug repurposing — identifying new clinical indications for approved or investigational compounds — has moved from a
Get fresh news and insights, drug patent expirations & more…
